A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.
| Condition(s) | Advanced Gynecological Malignancy |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer. |
| Who can participate | Inclusion Criteria: 1. Participate in the study voluntarily, sign the informed consent form. 2. Recurrent or metastatic gynecological malignancies that had failed standard treatments. 3. At least one measurable lesion (RECIST version 1.1). 4. ECOG 0\~ 1. 5. With adequate organ functions. 6. Female participants of childbearing potential must agree to use highly effective contraception during the treatment period and for at least 7 months after the last dose of SHR-A2102，Female participants' HCG must be negative within 72 hours prior to enrollment and must be non-lactating. Exclusion Criteria 1. With untreated brain metastasis or concomitant meningeal metastasis and spinal cord compression. 2. Previous or contemporaneous malignancies, unless these malignancies reached complete remission at l |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Lead sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Locations | Guangzhou, Guangdong, China |
| Start date | 2024-11-15 |
| NCT ID | NCT06654440 |
| Official listing | https://clinicaltrials.gov/study/NCT06654440 |